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A signature of saliva-derived exosomal small
RNAs as predicting biomarker for esophageal
carcinoma: a multicenter prospective study
Kai Li1, Yusheng Lin2,3,4, Yichen Luo1, Xiao Xiong1, Lu Wang1, Kameron Durante5, Junkuo Li6, Fuyou Zhou6,
Yi Guo7, Shaobin Chen8, Yuping Chen8, Dianzheng Zhang5, Sai‑Ching Jim Yeung9 and Hao Zhang10,11*

Abstract
Background: The tRNA-derived small RNAs (tsRNAs) are produced in a nuclease-dependent manner in responses to
variety of stresses that are common in cancers. We focus on a cancer-enriched tsRNA signature to develop a salivary
exosome-based non-invasive biomarker for human esophageal squamous cell carcinoma (ESCC).
Methods: Cancer-enriched small RNAs were identified by RNA sequencing of salivary exosomes obtained from
ESCC patients (n = 3) and healthy controls (n = 3) in a pilot study and further validated in discovery cohort (n = 66). A
multicenter prospective observational study was conducted in two ESCC high-incidence regions (n = 320 and 200,
respectively) using the newly developed biomarker signature.
Results: The tsRNA (tRNA-GlyGCC-5) and a previously undocumented small RNA were specifically enriched in salivary
exosomes of ESCC patients, ESCC tissues and ESCC cells. The bi-signature composed of these small RNAs was able to
discriminate ESCC patients from the controls with high sensitivity (90.50%) and specificity (94.20%). Based on the bisignature Risk Score for Prognosis (RSP), patients with high-RSP have both shorter overall survival (OS) (HR 4.95, 95%CI
2.90–8.46) and progression-free survival (PFS) (HR 3.69, 95%CI 2.24–6.10) than those with low-RSP. In addition, adju‑
vant therapy improved OS (HR 0.47, 95%CI 0.29–0.77) and PFS (HR 0.36, 95%CI 0.21–0.62) only for patients with high
but not low RSP. These findings are consistent in both training and validation cohort.
Conclusions: The tsRNA-based signature not only has the potential for diagnosis and prognosis but also may serve
as a pre-operative biomarker to select patients who would benefit from adjuvant therapy.
Trial registration: A prospective study of diagnosis biomarkers of esophageal squamous cell carcinoma, ChiCTR2000
031507. Registered 3 April 2016 - Retrospectively registered.
Keywords: Transfer RNA-derived small RNA, tRNA-derived fragments, Sequencing of salivary extracellular vesicles,
Liquid-biopsy signature, Pre-operative biomarker of adjuvant therapy, Esophageal carcinoma

*Correspondence: haolabcancercenter@163.com
10
Department of General Surgery, The First Affiliated Hospital of Jinan
University, and Institute of Precision Cancer Medicine and Pathology,
School of Medicine, Jinan University Medical College, 601 Huangpu
Avenue West, Guangzhou 510632, Guangdong, China
Full list of author information is available at the end of the article

Background
Esophageal squamous cell carcinoma (ESCC) is ranked
seventh for cancer morbidity and sixth for cancer mortality worldwide [1]. Patients often present at an advantage stage with lymph node metastasis at the time
of diagnosis, which leads to a 5-year survival rate of
approximately 20% [2–4]. To maximize the chance for
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eligibility for curative surgical resection, early detection
and diagnosis of ESCC is expected to be important. Currently, biomarkers suitable for detection of early stage
ESCC are lacking. Besides, loco-regional recurrence
occurs in 30 to 40% of patients after surgical resection
with intention to cure. Adjuvant radiotherapy and chemotherapy was important for ESCC, but their clinical
benefit is controversial [5–7]. There are no biomarkers
for predicting benefits of adjuvant therapies for ESCC
either. Thus, early detection of patients and more precise
stratification to guide adjuvant treatments are urgently
needed for this malignancy.
Endoscopic examination with biopsy is invasive, and
imaging studies are insensitive as screening modalities
for ESCC. Minimally invasive technologies such as cytosponge or transnasal endoscopy have cost and discomfort
barriers to wide-spread acceptance as screening methods for ESCC. Recently, liquid biopsy has been widely
investigated for non-invasive cancer detection, and it is
mainly based on three core types of biological materials originating from the cancer: circulating tumor cells
(CTCs), circulating tumor DNA (ctDNA), and exosomes
[8]. Despite their potential, the use of ctDNA and CTC
as liquid biopsy methods have several limitations. Given
that the fraction of ctDNA in total cell-free DNA is usually scarce, often < 0.01% [9, 10], detection sensitivity
is a serious concern, especially for early cancer detection [10]. In addition, the translation of CTC into clinical practice is limited by challenges of their isolation due
to extreme rarity, fragility, and oncogenetic/phenotypic
heterogeneity [10, 11]. In contrast, exosomes are a type
of extracellular vesicles containing proteins, DNAs, and
RNAs representative of many characteristics of the cells
from which they are secreted [12]. Exosomes are secreted
by various types of cells and reflect heterogeneous biological changes associated with the tumors.
Exosomes contain many types of small RNA, such as
miRNA, piwi-interacting RNA (piRNA), small nucleolar
RNA (snoRNA), tRNA-derived small RNAs (tsRNAs),
and other unidentified small RNAs [13–16]. Although
miRNAs are the most studied category of small RNA
biomarkers in exosomes, other exosome-derived small
RNAs are emerging as novel cancer-enriched diagnostic and prognostic biomarkers [16, 17]. tsRNAs (also
called tRNA-derived fragments (tRFs)), which were consider to be degradation products initially, are novel small
non-coding RNAs (sncRNAs) generated from precursor
or mature tRNAs [18–20]. tsRNAs were produced in a
nuclease (angiogenin, RNY1, Dicer) dependent manner in response to stress such as amino acid starvation,
oxidative stress and hypoxia [18, 21, 22]. It’s easy to conflate tsRNAs with cancer since the tumor microenvironment is characterized by hypoxia and nutrient deficiency.
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Recent studies have found that tsRNAs are dysregulated
in various types of cancer [23–25]. However, the exploration of the potentials of tsRNA-based liquid biopsy is at
an early stage [23–25].
Compared to ctDNA and CTCs that require phlebotomy to obtain liquid biopsy samples, exosomes are
present in virtually all bodily fluids such as blood, saliva,
urine, and cerebrospinal fluid, broadening the choices of
sample sources for liquid biopsy. We previously developed
salivary exosome-based detection of chimeric RNAs and
mRNAs as a non-invasive liquid biopsy method for diagnosis and monitoring the progression of diseases [26–28].
In this study, by comparing the small RNAs in salivary
exosomes of ESCC patients with that of healthy controls,
we discovered two cancer-enriched small RNAs, tRNAGlyGCC-5 and a previously uncharacterized small RNA
for which we coined the name “small RNA identified in
Exosome from Saliva of ESCC patients” (sRESE). The bisignature composed of the levels of these two salivary
exosomal small ncRNAs (abbreviated as sesncRNAs)
were evaluated for their potential as an ESCC biomarker
in a prospective multicenter observational study.

Methods
Study population

The study includes a pilot cohort (3 ESCC patients and
3 controls) and a discovery cohort (33 ESCC patients
and 33 controls) as detailed in Fig. 1A and B. A prospective multi-cohort clinical study (ChiCTR2000031507)
was registered on the Chinese Clinical Trial Registry
(http://www.chictr.org.cn). This study involves prospective observational cohorts from two institutions: The
Cancer Hospital of Shantou University Medical College
(CHSUMC, Shantou, Guangdong, China) and Anyang
Tumor Hospital (ATH, Anyang, Henan, China). As of
January 1, 2018, we recruited 237 patients who was
scheduled to undergo endoscopy and 137 healthy volunteers at CHSUMC, 166 patients who was scheduled to
undergo endoscopy and 74 healthy volunteers at ATH. A
total of 614 saliva samples were collected. The CHSUMC
cohort was for constructing the diagnostic and prognostic models, and the ATH cohort was for model validation.
Inclusion and exclusion criteria of those two cohorts are
shown in Fig. 1.
These studies were conducted under clinical protocols approved by the Institutional Ethics Committees and Review Board of Cancer Hospital of Shantou
University Medical College (CHSUMC) (IRB serial
number: #04–070) and Anyang Tumor Hospital
(ATH) (AZLL022016008161201). We obtained written informed consents from all participants per the
principles established by the Helsinki Declaration. The
cases recruited in this study were all newly diagnosed
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Fig. 1 Flow diagrams showing the design of the pilot cohort, discovery cohort and the two patient cohorts. A The pilot cohort. B The discovery
cohort. C The CHSUMC training cohort. D The ATH validation cohort

ESCC without prior anticancer treatment. The median
follow-up time was 37 months (range: 2–63). All
healthy subjects were approached for participation in
the study in public spaces (e.g., parks, senior activity
centers, and shopping areas) of the respective cities
and matched to at least one ESCC case for gender, age,
and tobaccos use. The healthy controls were excluded
if they had any history of malignancy, severe oral disease, diabetes mellitus, lung disease, renal or hepatic
dysfunction, severe immune alterations, and cardiovascular event in the past 6 months.

Clinicopathological characteristics and clinical outcomes

The demographic and clinical data (age, sex, pathologic
diagnosis, cancer treatment, etc.) were obtained from
electronic medical record databases. The pathologic
staging was done according to the Union for International Cancer Control (UICC) Tumor-Node-Metastasis
(TNM) staging system (7th edition) [29]. Stage I and II
were classified as the early-stage, and stage III and IV the
late-stage. Progression-free survival (PFS) was defined as
the duration from the time of ESCC primary surgery to
the first relapse at any body site or death of any causes,
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whichever occurred first. Overall survival (OS) was
defined as the duration from ESCC diagnosis to death of
any causes.
Statistical analysis

Comparisons between independent groups were performed with the t test or one-way ANOVA with post
hoc intergroup comparisons, where appropriate [30,
31]. Data were tested for normal distribution using the
Shapiro-Wilk test, and the Brown-Forsythe test was used
to evaluate for equal variance. For non-parametric comparison between two groups, a rank-sum test (Wilcoxon
matched-pairs signed-ranks test) would be used.
The sample size of the discovery cohort was determined a priori. Based on an estimated accrual interval
of 36 months and additional follow-up after the accrual
interval of up to 60 months, 33 cases and 33 controls
would be needed to reject the null hypothesis. Their survival curves were equal with a power > 0.800 if the median
survival of patients was 40 months and that the controls
were > 60 months. The Type I error probability for the
analysis was 0.05.
The differences of proportions in clinicopathological
characteristics were analyzed with the Chi-square test,
and the correlations between continuous variables were
evaluated using Pearson’s correlation test. The area under
receiver operating characteristics curve (AUROC) was
used to assess the predictive performance of sesncRNAs.
The optimal cutoff value for classification using sesncRNAs was based on the Youden index.
Survival analyses used the Kaplan-Meier method and
were compared by the log-rank test as well as univariate and multivariate Cox proportional hazards modeling. A backward stepwise approach was applied in the
discovery phase to identify the highly predictive sesncRNAs. Final Cox proportional hazards models were
constructed using a sesncRNA-signature. Age, gender,
histologic differentiation, tumor length, and stage as
covariates, and the models were evaluated for validity
by the Score test and calculating Martingale and Schoenfeld residuals using R package “ggcoxdiagnostics.”
A nomogram was formulated based on the results of
multivariate analysis using the R package “rms.” The
performance of the nomogram was assessed by the
concordance index (C-index) and by comparing nomogram-predicted survival with Kaplan-Meier estimates of
survival probability [32].
We used G*power (https://www.psychologie.hhu.de/
arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower.html) for a priori estimation of sample
size [33]. All other statistical analyses were conducted
using R, version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/). A P
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value of < 0.05 was considered to be significant, and all
tests were 2-sided.
Details for sample collection and experimental process
are included in supplementary materials and methods.

Results
Discovery

For the pilot study of 3 ESCC patients and 3 healthy
volunteers (Fig. 1A), the isolated exosomes from either
saliva or cell lysate were confirmed by TEM (Fig. S1A)
and immunoblot using antibodies against specific exosomal markers (Alix, TSG101, CD63, CD9) and Calnexin,
an intracellular protein that is not present in exosomes
(Fig. S1B). Nanoparticle tracking showed that the average
diameter of exosomes from saliva was 95 nm (Fig. S1C).
Compared to the controls, 1366 differentially (p < 0.05)
expressed sesncRNAs (excluding miRNAs) were identified in ESCC patients. Among them, 32 were highly
expressed in ESCC patients with log2 fold changes > 2,
and the top five candidates with the most significant fold
changes were selected for further investigation (Fig. 2A).
Totally, 33 ESCC patients and 33 controls were
recruited at CHSUMC to evaluate the levels of the top
five sesncRNAs by RT-qPCR (Fig. 1B). Two of the five
sesncRNAs met the predetermined significance level of
0.01 (Fig. 2B). Both of them, tsRNA (tRNA-GlyGCC-5)
[34] and a previously uncharacterized small non-coding
RNA, located in chromosome 1. Blast analysis on the
National Center for Biotechnology Information (NCBI)
found that tRNA-GlyGCC-5 is derived from 5’end of
TRG-GCC. Further analysis found that sRESE gene
resided between SSX2IP and lncRNA LOC102724892.
Since this uncharacterized RNA is a small RNA identified
in Exosomes from the Saliva of ESCC patients, we named
it sRESE. The expression levels of these two sesncRNAs
were examined in exosomes (Fig. S2A) and cell lines (Fig.
S2B). Compared to the immortalized esophageal epithelial cells, both tRNA-GlyGCC-5 and sRESE were highly
expressed in exosomes secreted into the conditioned
media and ESCC cell lines. Sanger sequencing furthermore confirmed that these sesncRNAs were present and
detectable in exosomes (Fig. S3). To understand the biological role of these sesncRNAs, we transfected ESCC
cells with antisense RNAs against sesncRNAs, and found
that proliferation, migration, and invasion were all significantly suppressed in both KYSE150 (Fig. 2C) and TE-12
cells (Fig. S4) suggesting that these sesncRNAs could be
involved in the regulation of cell proliferation, migration,
and invasion.
Detection of the presence of ESCC

A prospective study (ChiCTR2000031507) is currently
underway to collect saliva samples to study exosomal
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Fig. 2 Identification of cancer-enriched sesncRNAs in salivary exosomes of ESCC patients. A The heatmap showing the top five differently
expressed small RNAs by small RNA-seq of salivary exosomes. B Confirmation of the differentially expressed salivary RNAs. C Effect of sesncRNAs
on cell migration and invasion. All experiments were performed in biological triplicate. D-E The box and scatter plots of tRNA-GlyGCC-5 (left) and
sRESE (right) in the CHSUMC cohort (D) and the ATH cohort (E). F The results of ROC analysis of sesncRNAs in the CHSUMC cohort. SEM (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 by unpaired t-test)

biomarkers. Since the pre-specified sample size has not
been reached, the study is still ongoing. The demographic
and clinicopathological characteristics of the patients in
this interim analysis were summarized in Table 1. We
analyzed the levels of these sesncRNAs in the salivary
samples collected as of January 1, 2018 (Fig. 1C and D)
and found that both tRNA-GlyGCC-5 and sRESE were
significantly (p < 0.001) increased in ESCC patients compared with healthy volunteers in both CHSUMC cohort
(200 ESCC patients and 120 controls, Fig. 2D) and ATH
cohort (140 ESCC patients and 60 controls, Fig. 2E). In

addition, the AUROC for tRNA-GlyGCC-5 and sRESE is
0.878 and 0.871, respectively, in the CHSUMC subjects
(training cohort) (Fig. 2F). Using the optimal cutoff values for tRNA-GlyGCC-5 and sRESE determined using
the Youden indices in the receiver operating characteristics analyses of the training cohort, the sensitivity of
tRNA-GlyGCC-5 and sRESE in the prediction of ESCC
is 79.00 and 77.00%, respectively, for the training cohort
(Table 2).
To investigate the efficacy of a bi-sesncRNA signature
(tRNA-GlyGCC-5 and sRESE), we performed a logistic
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Table 1 Patient demographics and clinicopathological characteristics of the training and validation cohorts
CHSUMC cohort
Variables

P value

ATH cohort

P value

P value

Healthy

Patient

Healthy

Patient

(n = 120)

(n = 200)

(n = 60)

(n = 140)

n (%)

n (%)

n (%)

n (%)

60.69 ± 8.66

61.06 ± 9.05

0.720B

61.13 ± 9.20

61.24 ± 8.65

0.936B

0.852B

Female

50 (41.7)

74 (37.0)

0.410A

25 (41.7)

47 (33.6)

0.335A

0.566A

Male

70 (58.3)

126 (63.0)

35 (58.3)

93 (66.4)

T1/T2

NA

58 (29.0)

NA

52 (37.1)

T3/T4

NA

142 (71.0)

NA

88 (62.9)

Negative

NA

85 (42.5)

NA

70 (50.0)

Positive

NA

115 (57.5)

NA

70 (50.0)

41 (20.5)

NA

18 (12.9)

Age (years)
Gender

Tumor depthC
0.126A

Lymph node metastasis
0.185A

Histological differentiation
Poor

NA

0.179A

Moderate

NA

99 (49.5)

NA

78 (55.7)

Well

NA

60 (30.0)

NA

44 (31.4)

4.86 ± 1.45

NA

5.01 ± 1.44

0.319B

0.148A

Largest tumor dimen‑ NA
sion (cm)
TNM Stage
I/II

NA

78 (39.0)

NA

66 (47.1)

III/IV

NA

122 (61.0)

NA

74 (52.9)

For categorical variables, the number of patients was shown as n (%); quantitive variables were mean ± SD
A

χ2 test was used for comparing control and patient group

B

Unpaired t test was used for comparing control and patient group

C

Tumor depth indicated that how deeply tumor cells have invaded

Table 2 Performance of sesncRNAs test to differentiate ESCC patients from healthy subjects in CHSUMC and ATH cohorts
Variables

Cohorts

Cancer

Test Positive (n)

Test
Negative
(n)

Total (n)

Sensitivity

Specificity

PPV

NPV

tRNA-GlyGCC-5

CHSUMC

Absent

10

110

120

79.00%

91.67%

94.05%

72.37%

Present

158

42

200

Total

168

152

320

Absent

14

106

120

77.00%

88.33%

91.67%

69.73%

Present

154

46

200

Total

168

152

320

Absent

7

113

120

90.50%

94.20%

96.28%

85.61%

Present

181

19

200

Total

188

132

320

Absent

9

51

60

87.14%

85.00%

93.13%

75.00%

Present

122

18

140

Total

131

68

200

sRESE

Bi-sesncRNA signature

CHSUMC

CHSUMC

ATH

PPV positive predictive value, NPV negative predictive value
The cutoff value calculated in CHSUMC cohort was applied in the ATH cohort
Test Positive in this analysis is based on a sesncRNA level or RSD higher than cutoff value; the remaining individuals were classified as Test Negative
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regression analysis using the expression values of tRNAGlyGCC-5 and sRESE to predict the presence of ESCC.
The bi-sesncRNA signature risk score for diagnosis (RSD)
was defined as:

2.93 [1.82–4.72]; PFS: HR 3.69 [2.24–6.10] vs 2.22 [1.41–
3.50] or 2.46 [1.53–3.94]).
When the ESCC patients in the ATH cohort were
divided into high-RSP or low-RSP groups using the
above-defined cutoff value (− 0.436), Kaplan-Meier


RSD = 111.01 x expression value of tRNA − GlyGCC − 5 +27.198 x (expression value of sRESE)−4.029.

ROC analysis indicated that the bi-sesncRNA signature RSD has better performance than each sesncRNA
alone (AUROC 0.933 vs. 0.878 or 0.871, Delong test, both
p < 0.001). Based on the optimal cutoff value (0.040) of
the Youden index obtained from the ROC curve, ESCC
patients in the CHSUMC cohort could be discriminated
from controls by the RSD with a sensitivity of 90.50% and
a specificity of 94.20%. Additionally, the positive predictive value (PPV) was 96.28%, and the negative predictive value (NPV) was 85.61% (Table 2). The cutoff value
from the CHSUMC training cohort was then applied in
the ATH validation cohort and found that the sensitivity, specificity, PPV, NPV are 87.14, 85.00, 93.13, 75.00%,
respectively (Table 2). Interestingly, based on this cutoff,
patients with stage I ESCC could also be discriminated
from controls both in CHSUMC and ATH cohorts (Table
S1). Therefore, the bi-sesncRNA signature could robustly
distinguish ESCC (including stage I disease) patients
from healthy subjects, thus promising a high translational potential.

analysis revealed that compared to those with low-RSP
the patients with high-RSP have shorter OS (Fig. 3D,
HR = 2.06, 95%CI 1.23–3.46, p = 0.005) and PFS (Fig. 3H,
HR = 2.05, 95%CI 1.21–3.46, p = 0.006), suggesting that
bi-sesncRNA-derived high RSP can serve as an indicator for good prognosis of ESCC. The multivariate COX
regression analysis indicates that the histological differenciation, bi-sesncRNA signature RSP and TNM stage
were independent prognostic factors for OS and PFS of
both CHSUMC and ATH cohorts (Table 4 and S2). To
seek more precise prediction for an individual ESCC
patient’s survival while controlling for TNM stage and
histological differentiation, a nomogram prediction
model was established based on multivariate regression
analysis (Fig. 4A). The 3-year-OS were predicted well in
both CHSUMC cohort (Fig. 4B, C-index = 0.718) and
ATH cohort (Fig. 4C, C-index = 0.711). These findings
collectively demonstrated that the bi-sesncRNA signature RSP could serve as an independent predictor for the
clinical outcomes of ESCC.

Prognostic prediction of ESCC

Prediction of benefit of adjuvant therapy

To assess the potential clinical utility of a bi-sesncRNA
signature score in ESCC prognosis, we developed logistic
regression formula to model the prediction of vital status to calculate a Risk Score for Prognosis (RSP) for each
patient based on the two sesncRNAs expression levels:

We next examined the instructive role of the bi-sesncRNA
signature RSP in postoperative adjuvant treatment. Using
the above-established cutoff value (− 0.436) of bi-sesncRNA-derived RSP, patients were stratified into high-RSP
and low-RSP groups to retrospectively analyze the effect
of adjuvant therapy on ESCC clinical outcomes. In the


RSP = 22.979 x expression value of tRNA − GlyGCC − 5 +5.741 x (expression value of sRESE)−2.199.

The medians of tRNA-GlyGCC-5, sRESE, and bi-sesncRNA signature RSP were used to divide the patients in
the CHSUMC cohort into high (above median) and low
(at or below median) groups. The bi-sesncRNA signature
RSP is highly correlated with the lymph node metastasis,
and histological differentiation (Table 3). Kaplan-Meier
analysis revealed that ESCC patients with high-RSP have
a significantly shorter OS (Fig. 3C, HR = 4.95, 95%CI
2.90–8.46, p < 0.001) and PFS (Fig. 3G, HR = 3.69, 95%CI
2.24–6.10, p < 0.001) than those with a low-RSP. Notably, the bi-sesncRNA signature improved the prediction
of OS and PFS than either sesncRNA alone (Fig. 3A and
B, OS: HR 4.95 [95%CI 2.90–8.46] vs 2.63 [1.65–4.19] or

CHSUMC cohort, 54 ESCC patients with high RSP and
41 ESCC patients with low RSP received adjuvant therapy.
When the Kaplan-Meier survival analysis was stratified by
the bi-sesncRNA signature RSP, we found that adjuvant
therapy was associated with an improved OS (Fig. 5A, HR
0.47, 95%CI 0.29–0.77; p = 0.002) and PFS (Fig. 5E, HR
0.36, 95%CI 0.21–0.62; p < 0.001) in patients with high-RSP
but not those with low-RSP value (Fig. 5B&F, OS: HR 0.62,
95%CI 0.22–1.77; p = 0.370; PFS: HR 1.06, 95%CI 0.44–
2.51; p = 0.903). Similar findings were observed in the ATH
cohort (High-RSP patients, OS: HR 0.28, 95%CI 0.12–0.70;
p = 0.003; PFS: HR 0.32, 95%CI 0.13–0.78; p = 0.008. LowRSP patients, OS: HR 0.71, 95%CI 0.32–1.58; p = 0.403;
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Table 3 Association of tRNA-GlyGCC-5 expression, sRESE expression and bi-sesncRNAs signature RSP with demographic and
clinicopathological characteristics of the CHSUMC cohort
Variables

Patients: n

tRNA-GlyGCC-5 level
Low: n (%)

P value

High: n (%)

sRESE level

P value

Low: n (%)

High: n (%)

Bi-sesncRNA signature
Low: n (%)

High: n (%)

100 (50.0)

100 (50.0)

60.19 ± 8.57

61.93 ± 9.47

0.175B
0.232 A

Total samples

200

100 (50.0)

100 (50.0)

100 (50.0)

100 (50.0)

Age (years)

200

59.99 ± 8.73

62.13 ± 9.28

0.095B

60.58 ± 8.67

61.54 ± 9.44

0.455B

Female

74

32 (43.2)

42 (56.8)

0.094A

33 (44.6)

41 (55.4)

0.153A 34 (45.9)

40 (54.1)

Male

126

68 (54.0)

58 (46.0)

67 (53.2)

59 (46.8)

66 (52.4)

60 (47.6)

T1/T2

58

32 (55.2)

26 (44.8)

37 (63.8)

21 (36.2)

0.009A 31 (53.4)

27 (46.6)

T3/T4

142

68 (47.9)

74 (52.1)

63 (44.1)

79 (55.6)

69 (48.6)

73 (51.4)

55 (64.7)

30 (35.3)

< 0.001A 52 (61.2)

33 (38.8)

45 (39.1)

70 (60.9)

48 (41.7)

67 (58.3)

39 (65.0)

21 (35.0)

0.012A 43 (71.7)

17 (28.3)

Gender

P value

Tumor depth
0.218A

0.320A

Lymph node metastasis
Negative

85

54 (63.5)

31 (36.5)

Positive

115

46 (40.0)

69 (60.0)

40 (66.7)

20 (33.3)

0.001A

0.005A

Histological differentiation
Well

60

0.007A

< 0.001A

Moderate

99

44 (44.4)

55 (55.6)

46 (46.5)

53 (53.5)

41 (41.4)

58 (58.6)

Poor

41

16 (39.0)

25 (61.0)

15 (36.6)

26 (63.4)

16 (39.0)

25 (61.0)

4.70 ± 1.64

5.01 ± 1.22

0.135B

4.82 ± 1.56

5.10 ± 1.60

0.217B

4.84 ± 1.69

5.09 ± 1.45

0.256B

0.029A

47 (60.3)

31 (39.7)

0.029A 43 (55.1)

35 (44.9)

0.310A

53 (43.4)

69 (56.6)

57 (46.7)

65 (53.3)

Largest tumor
200
dimension (cm)
Stage
I/II

78

47 (60.3)

31 (39.7)

III

122

53 (43.4)

69 (56.6)

High in this analysis is based on a salivary exosomal sesncRNA level or RSP higher than median; the remaining individuals were classified as low
A

χ2 test was used for comparing control and patient group

B

Unpaired t test was used for comparing control and patient group

PFS: HR 1.05, 95%CI 0.49–2.27; p = 0.898.), in which 55 of
the140 patients received adjuvant therapy (Fig. 5C-D and
G-H). To avoid the influence of the bias of clinicopathological characteristics of patients with or without adjuvant
therapy, χ2 test was performed and no significantly difference was found in these two groups (Tables S3 and S4).
The results of this analysis suggested that only the ESCC
patients with high bi-sesncRNA signature RSP might
benefit from adjuvant therapy to improve their PFS and
OS. Therefore, the bi-sesncRNA signature RSP might be
a potential tool to predict which pre-operative patients
might benefit from adjuvant therapy.

Discussion
In this study, two previously uncharacterized small
RNAs, tsRNA (tRNA-GlyGCC-5) and a previously
unnamed small RNA (coined name: sRESE) were identified using high-throughput sequencing of small RNAs
in salivary exosomes derived from ESCC patients.
In a prospective clinical study, a bi-sesncRNA signature (composing of tRNA-GlyGCC-5 and sRESE) was
found to serve as a non-invasive biomarker for ESCC

diagnosis and prognosis as well as for prediction of
adjuvant therapeutic benefits.
The bi-sesncRNA signature described here was identified by directly sequencing of exosomes derived from
patients’ saliva. To trace the origin of the exosomederived small RNAs, both tRNA-GlyGCC-5 and sRESE
were validated in patients’ tissue as well as in ESCC
cell lines. Furthermore, we found that ESCC cell lines
secreted exosomes that contained these two small
RNAs into conditioned culture media. Since the salivary exosomes of ESCC patients were enriched in these
two small RNAs compared to healthy volunteers, the
source or the cause of enrichment in salivary exosomes
of ESCC patients was likely to be ESCC. This potential
link between secretion of exosomes containing these
two RNAs by ESCC cells and increased amount of them
in salivary exosomes from ESCC patients suggested
that their amounts in salivary exosomes might have
diagnostic and/or prognostic value. Although tsRNAs
in exosomes were investigated in some published studies [16, 35–37], this is the first report of salivary exosomal tsRNA as a disease biomarker.
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Fig. 3 Performance of sesncRNAs for prognostication in CHSUMC and ATH cohorts. A-B and E-F Kaplan-Meier analysis shows that the OS and PFS
were significantly longer in patients with low expression of tRNA-GlyGCC-5 (A and E) or sRESE (B and F) than those with high expression. C and G
The sesncRNAs-based Risk Score for Prognosis (RSP) of each patient. Kaplan-Meier analysis shows that patients with low-RSP have longer OS (C)
and PFS (G) than those with high-RSP in the CHSUMC cohort. D and H OS (D) and PFS (H) were significantly longer in patients with low RSP than
those with high RSP in the ATH cohort. The p-values were calculated using the unadjusted log-rank test and hazard ratios (HR) using univariate Cox
regression. CI, confidence interval

Table 4 Univariate and multivariate Cox proportional hazards analyses of survival in ESCC patients of CHSUMC cohort
Variables

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

1.258 (0.817 to 1.936)

0.297

0.938 (0.596 to 1.475)

0.782

0.792 (0.502 to 1.249)

0.315

0.656 (0.399 to 1.078)

0.096

1.708 (1.247 to 2.339)

0.001

1.473 (1.039 to 2.088)

0.030

1.748 (1.120 to 2.728)

0.014

1.520 (0.955 to 2.421)

0.078

Age (years)
  > 60 vs. ≤60

Gender

Male vs. Female
Histological differentiation
Poor vs. Well/Moderate
Largest tumor dimension (cm)
  
≥ 5 vs. < 5

TNM Stage
III vs. I/II

Bi-sesncRNA signature

2.709 (1.645 to 4.463)

< 0.001

1.688 (0.985 to 2.894)

0.057

2.062 (1.678 to 2.535)

< 0.001

1.983 (1.550 to 2.535)

< 0.001

HR hazard ratio, CI confidence interval

The analysis of two prospective observational cohorts
(one as training cohort and the other as validation
cohort) demonstrated that a bi-sesncRNA signature
RSD performed better than either small RNA alone
for predicting the presence of ESCC. Interestingly, this

RSD exhibited a good negative predictive value in discriminating stage I patients from healthy controls, thus
a high potential for translating the bi-sesncRNA signature for future prospective ESCC screening. The bisesncRNA signature RSP also performed better than
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Fig. 4 Nomogram to predict the probability of survival of ESCC patients using the bi-sesncRNAs RSP. A ESCC survival nomogram. The calibration
curve for predicting OS at 3 years in the CHSUMC (B) and ATH (C) cohort. Nomogram-predicted probability of survival is plotted on the x-axis; actual
overall survival is plotted on the y-axis

either small RNA alone for predicting ESCC prognosis. Although there are some diagnostic or prognostic biomarkers for ESCC already reported [38–41],
the bi-sesncRNA signature exhibits high sensitivity
and specificity. However, future direct head-to-head
comparisons in clinical studies are required to establish superiority of the bi-sesncRNA signature for early
screening and prognosis of ESCC.

Prognostic assessment is a crucial consideration in the
decision to undergo adjuvant therapy. In routine clinical
practice, the TNM staging of ESCC is the major prognostic determinant. However, there is still considerable
variation in the clinical outcomes of ESCC patients perhaps due to heterogeneity caused by unmeasured covariates. In this study, we developed a bi-sesncRNA signature
that effectively predicted the survival and therapy benefit
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Fig. 5 RSP for prognostication of survival and treatment prediction for postoperative therapy. A and B The benefit of postoperative therapy in
patients classified as high-RSP in CHSUMC cohort. C and D The benefit of postoperative therapy in patients with low-RSP in CHSUMC cohort. E
and F The benefit of postoperative therapy for patients with high-RSP in ATH cohort. G and H The benefit of postoperative therapy for patients
with low-RSP in CHSUMC cohort. The p-values were calculated using the unadjusted log-rank test, and hazard ratios (HR) using a univariate Cox
regression analysis. CI, confidence interval

of ESCC patients. In Cox regression models to predict
OS or PFS, the HRs for the RSP and TNM stage were
1.983 and 1.688; therefore, the bi-sesncRNA signature
RSP and TNM stage were both independent predictors,
and the bi-sesncRNA signature is as influential as TNM
stage, if not more. To our knowledge, this is the first preoperative biomarker for predicting benefits of postoperative adjuvant therapy for ESCC. These small RNAs with
their functions in promoting tumor progression are the
high-risk biomarker for cancer progression after surgery. We found that high-RSP patients tend to benefit
from adjuvant therapy, as elevated RSP indicating the
urgent need of postoperative therapy. On the contrast,
low-RSP patients did not benefit from adjuvant therapy
suggesting that these patients should not be treated with
these therapies after surgery to avoid the both adjuvant
treatment-related side effect and financial cost. Therefore, this bi-sesncRNA signature have the potential to
help clinicians develop more precise treatment plans and
avoid futile or unnecessary adjuvant treatments for ESCC
patients.
The salivary exosome-detection of small RNA offers
several unique advantages: a) representation of the malignancy as a whole and not just the biopsy site, particular

group of cancer cells or individual cancer cells compared
with tissue-based assays; b) non-invasive and reproducible, and more convenient to obtain than blood; c) more
layers of molecular/genetic information compared with
circulating tumor DNA (ctDNA); d) less technically challenging than circulating tumor cells (CTC). Multiple proteomic, transcriptomic, and metabolomics studies have
demonstrated that saliva contains biomolecules that are
effective indicators of oral and systemic diseases [42, 43].
Ogawa Y et al. have investigated the small RNA profile
in a healthy human salivary exosome [44], supporting
that nuclear acids from salivary exosomes were stable
biomarkers. Our previous study also observed that salivary exosomal chimeric RNA can serve as a non-invasive
approach for molecular cancer detection, monitoring of
tumor burden, and surveillance of treatment response
[26]. To our knowledge, current study is the first clinical
study to investigate salivary exosome-based cancer biomarkers. It is also the first clinical trial of salivary exosomal small RNAs as cancer biomarkers.
Prior to the current study, both tRNA-GlyGCC-5 and
sRESE are uncharacterized especially for their functions, although tRNA-GlyGCC-5 was reported to
be detected in malignant human B cells [34]. sRESE
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resides in chromosome 1, adjacent between SSX2IP and
LOC102724892. SSX2IP was reported promoting metastasis and chemotherapeutic resistance in hepatocellular
carcinoma and relating poor outcomes of nasopharyngeal
carcinoma [45, 46], while LOC102724892 is a lncRNA
gene whose function remains unknown. This study demonstrated that both tRNA-GlyGCC-5 and sRESE promote proliferation, migration, and invasion functionally.
The specific mechanisms by which tRNA-GlyGCC-5 and
sRESE promote tumor progression remain incomplete
and require further exploration.
One limitation of our study was that the follow-up
time of many patients in our cohorts were under 5 years;
therefore, our data could only support generation of
the nomogram for 3-year survival. Besides, the current
report is an interim analysis of the clinical trial, which
may introduce uncertainty because the trial is ongoing.
To avoid misleading results, more samples were enrolled
for analysis and establishing the model. Upon full recruitment to the study and longer follow up time, more robust
statistical analysis and generation of the nomogram for
5-year survival will be reported.

Conclusions
In this study, we discovered a cancer-enriched bi-sesncRNA signature (i.e., tRNA-GlyGCC-5 and sRESE) in
salivary exosomes, which represents a non-invasive,
convenient, and reliable biomarker for human ESCC
diagnosis, prognosis, and particularly, prediction of preoperative patients who likely to benefit from adjuvant
therapy. Further extensive independent prospective randomized studies are needed to validate the clinical application of this bi-sesncRNA signature.
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